Hu Zhou | Hematology | Excellence in Research Award

Published on by Global Academic Awards

Prof. Dr. Hu Zhou | Hematology | Excellence in Research Award

Henan Cancer Hospital | China

Prof. Dr. Hu Zhou is a leading hematology researcher recognized for his extensive work on the pathogenesis and clinical management of blood disorders, particularly immune thrombocytopenia, myelodysplastic syndromes, myeloproliferative neoplasms, and thrombosis–hemostasis abnormalities. With 621 citations, 78 published documents, and an h-index of 14, he has established a strong scholarly footprint in clinical and translational hematology. His research integrates clinical trials, molecular pathology, and mechanistic studies, contributing significantly to advances in immunoglobulin therapies, monoclonal antibodies, JAK2 inhibitors, and recombinant thrombopoietic agents. He has illuminated genetic polymorphisms, cytokine signaling pathways, and immune dysregulation mechanisms underlying chronic immune thrombocytopenia. His contributions further extend to leukemogenesis, epigenetic alterations in hematologic malignancies, and therapeutic optimization in refractory leukemia. As an active member of national and international hematology societies, he leads major funded research projects and has been recognized with multiple scientific achievement awards, reflecting his broad impact on hematologic innovation and patient-centered clinical advancement.

Profile: Scopus

Featured Publications

1. Zhou, H., et al. (2025). Efficacy and safety of a new 10% intravenous immunoglobulin (IVIG) in Chinese patients with primary immune thrombocytopenia (ITP): A multicenter, single-arm, phase III trial. Clinical and Experimental Medicine.

2. Zhou, H., et al. (2025). Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: Multicentre, randomised, placebo-controlled, phase 2 trial. BMJ Clinical Research Edition.

3. Zhou, H., et al. (2025). Efficacy and safety of OB756 (a novel selective JAK2 inhibitor) for essential thrombocythemia in patients intolerant of or resistant to hydroxyurea or intolerant of interferon: A phase 2, open-label, multicenter study. Cancer.

4. Zhou, H., et al. (2025). Hetrombopag for patients with persistent primary immune thrombocytopenia: A post hoc analysis of a multicenter, randomized phase III trial. Research and Practice in Thrombosis and Haemostasis.

5. Zhou, H., et al. (2025). Dose-optimised recombinant human thrombopoietin versus eltrombopag in patients with immune thrombocytopenia: A multicenter, randomised controlled trial (The TE-ITP Study). EClinicalMedicine.

Bing Xiu | Hematology | Best Researcher Award

Published on by Global Academic Awards

Prof. Bing Xiu | Hematology | Best Researcher Award

Prof. Bing Xiu | Tongji University | China 

Prof. Bing Xiu is an esteemed Associate Chief Physician and Vice Professor at the Department of Hematology, Tongji Hospital, Tongji University, Shanghai, China. With over two decades of experience in hematology, she holds a Ph.D. in Internal Medicine and has undertaken advanced training at the Mayo Clinic, USA. Prof. Xiu is a certified specialist in internal medicine and hematology and serves as a Master’s supervisor. Her research focuses on lymphoma, T-cell exhaustion, immunotherapy, and CAR-T related cytokine release syndrome. She has led and contributed to several major national and international research projects, including those funded by the NSFC and NIH. Prof. Xiu has published extensively in high-impact journals like Blood Cancer Journal, Leukemia, and Clinical Cancer Research, and has presented at ASH and ASCO, earning abstract honors. She also co-edited a clinical dataset book on diffuse large B-cell lymphoma and is active in several national medical associations and academic committees.

Publication Profile

Scopus

Education Background

Prof. Bing Xiu has pursued her entire medical education at the prestigious Medical College of Tongji University in Shanghai, China, demonstrating a consistent commitment to academic excellence and specialization in internal medicine. She began her journey in medicine by earning her Bachelor of Medicine degree from Tongji University, where she laid the foundational knowledge in clinical sciences. Her passion for hematology and internal medicine led her to further academic pursuit, completing her Master of Medicine from the same institution. With an increasing focus on clinical research and advanced therapeutics, Prof. Xiu earned her Ph.D. in Internal Medicine from Tongji University, focusing on cutting-edge areas of hematologic malignancies. This continuous and progressive educational pathway has equipped her with deep theoretical knowledge and advanced research capabilities that have significantly influenced her medical and academic career.

Professional Experience

Prof. Bing Xiu has built a distinguished career in hematology through extensive clinical, academic, and international experience. She serves as the Associate Chief Physician in the Department of Hematology at Tongji Hospital, Tongji University, Shanghai, where she also holds the role of Master’s supervisor. Her international exposure includes prestigious appointments as a Research Fellow and Visiting Clinician at the Mayo Clinic, Rochester, USA. Prof. Xiu’s earlier roles at Tongji Hospital include her tenure as a Fellow and as a Resident, marking a steady progression in her professional responsibilities. This rich blend of domestic and international clinical research and patient care has shaped her into a leader in hematology and academic mentorship.

Professional Certifications

Prof. Bing Xiu holds esteemed certifications that underscore her clinical expertise and professional standing in the field of internal medicine and hematology. She is certified by the Chinese Board of Internal Medicine, which affirms her comprehensive proficiency in diagnosing and managing a wide range of medical conditions. In addition, she possesses a specialized certification in Internal Medicine-Hematology from the same board, highlighting her focused expertise in the diagnosis and treatment of blood disorders, hematologic malignancies, and related immunological conditions. These dual certifications not only reflect her advanced clinical training but also qualify her to deliver high-level patient care, contribute to academic leadership, and mentor postgraduate students in hematology. Recognized by national regulatory authorities, these credentials form the foundation of her credibility and professionalism in China’s medical and academic community, supporting her roles in major research projects, teaching, and leadership in national medical societies.

Research Focus

Prof. Bing Xiu focuses her research on the molecular and translational mechanisms underlying hematologic malignancies, with particular emphasis on lymphomas and myeloproliferative neoplasms. Her recent publications explore critical areas such as germline mutations in lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH), indicating an interest in immune dysregulation and genetic predisposition in aggressive B-cell lymphomas. She has also investigated epigenetic and genetic alterations, such as single nucleotide polymorphisms and promoter methylation of protein tyrosine phosphatase 1B, in myeloproliferative disorders, showcasing her engagement in cancer genomics. Furthermore, her research integrates cutting-edge immunotherapies, including CAR T-cell therapy combined with autologous hematopoietic cell transplantation for refractory/relapsed Burkitt lymphoma, indicating her commitment to improving outcomes through personalized and cellular therapies. Collectively, her work lies at the intersection of cancer genetics, immunotherapy, and translational hematology, making significant contributions to advancing targeted and immune-based treatments for hematologic cancers.

Publication Top Notes

1. Germline mutations in B-cell non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH) and patient outcomes
Publication Year: 2025

2. Single nucleotide polymorphism and promoter methylation analysis of protein tyrosine phosphatase 1B in patients with myeloproliferative neoplasms
Publication Year: 2025

3. CAR T-cell therapy combined with autologous hematopoietic cell transplantation in patients with refractory/relapsed Burkitt Lymphoma
Publication Year: 2025
Citations: 1

Conclusion

Prof. Bing Xiu is highly suitable for the Best Researcher Award. Her record combines clinical excellence, high-impact hematological research (particularly in lymphoma and immunotherapy), international collaboration, grant leadership, and academic publishing. With a few more translational innovations or expanded global leadership, she would stand at the pinnacle of international medical research. As it stands, she is a top-tier candidate whose body of work exemplifies the award’s purpose to honor groundbreaking research with societal and scientific relevance.

 

 

Angelika Bátorová | Hematology | Best Researcher Award

Published on by Global Academic Awards

Prof. Dr. Angelika Bátorová | Hematology | Best Researcher Award

Prof. Dr. Angelika Bátorová , Faculty of Medicine, Comenius Universty, Bratislava, Slovakia

Prof. Dr. Angelika Bátorová is a leading Slovak hematologist, serving as Head of the Department of Hematology and Blood Transfusion and Director of the National Hemophilia Centre at University Hospital Bratislava. A professor at Comenius University, she is recognized internationally for her work in bleeding disorders, particularly hemophilia. With clinical leadership, research innovation, and educational roles, she has significantly contributed to advancing care standards in Slovakia and Europe. She has served on the Executive Committee of the World Federation of Hemophilia and other key advisory bodies. Her dedication continues through education, patient advocacy, and clinical research in hemostasis and thrombosis.

Publication Profile

Orcid

🔹 Education

Dr. Bátorová earned her MD and PhD from the Faculty of Medicine, Comenius University in Bratislava. She trained in Internal Medicine and later specialized in Hematology and Transfusion Medicine through the University Hospital and the Institute of Postgraduate Medicine. Her postgraduate training included prestigious fellowships at the National Hemophilia Centre in Tel Aviv, Israel, and the New York Blood Center, USA. She also trained at comprehensive hemophilia care centers across Europe. Her education and training laid a strong foundation for her career in clinical hematology, research, and leadership in bleeding disorder management at both national and international levels.

🔹 Experience

Prof. Bátorová is the Head of the Department of Hematology and Transfusion Medicine and Director of the National Hemophilia Centre at University Hospital Bratislava. She is a professor of Internal Medicine at Comenius University and serves as the Chief Expert for Hematology for the Slovak Ministry of Health. Her leadership transformed Slovakia’s hemophilia care, including establishing national registries and developing clinical protocols. She has led numerous working groups, participated in international research consortia, and contributed to global medical guidelines. Her experience spans clinical management, policy development, academic leadership, and mentorship in hematology and rare bleeding disorders.

🔹 Awards and Honors

In 1996, Dr. Bátorová received the prestigious award from the World Federation of Hemophilia (WFH) for her significant contributions to improving hemophilia care in Slovakia. She served as a past Executive Committee member of the WFH and as a member of the Medical Advisory Group of the European Hemophilia Consortium. She is also a former President of the Slovak Society of Hematology. Her ongoing leadership roles include Chair of the Slovak Hemophilia Working Group and active membership in EAHAD. She continues to be recognized for her scholarly work, leadership, and global impact on hematology and patient-centered care.

🔹 Research Focus

Prof. Bátorová’s research focuses on hemostasis, thrombosis, hemophilia, and rare bleeding disorders. She was instrumental in initiating Slovakia’s National Registry of hemophilia and the Hemophilia Gene Registry. Her clinical research emphasizes pharmacokinetic-guided prophylaxis, surgery management, care for patients with inhibitors, von Willebrand disease, and congenital factor deficiencies. She has authored numerous peer-reviewed papers, textbook chapters, and conference presentations. Her work has contributed to international guidelines and improved patient outcomes. As an editorial board member and journal reviewer, she maintains an active role in advancing scientific literature and ensuring quality standards in hematology research.

Publication Top Notes

  • 📘 Physical Activity Awareness and Understanding of Treatment Protection Among People With Haemophilia and Their Caregivers in Central Europe | 📅 2025 | 📰 Haemophilia | 🔗 DOI: 10.1111/hae.70038

  • 📘 Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia | 📅 2023 | 📰 Annals of Hematology | 🔗 DOI: 10.1007/s00277-023-05114-8

  • 📘 Immune tolerance induction in the era of emicizumab | 📅 2022 | 📰 Haemophilia | 🔗 DOI: 10.1111/hae.14470

  • 📘 25 years in comprehensive care and treatment of haemophilia | 📅 2019 | 📰 Transfuze a Hematologie Dnes

  • 📘 Comparison of two different techniques of warfarin dosing determination – A chemometrics study | 📅 2019 | 📰 Iranian Journal of Pharmaceutical Research | 🔗 DOI: 10.22037/ijpr.2019.1100653

  • 📘 Haematopoietic stem cell transplantation in patients with myelodysplastic syndrome – a single centre experience | 📅 2019 | 📰 Transfuze a Hematologie Dnes

  • 📘 The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab | 📅 2019 | 📰 Haemophilia | 🔗 DOI: 10.1111/hae.13762

  • 📘 The use of granulocyte colony stimulating factor after autologous hematopoietic stem cell transplantation | 📅 2019 | 📰 Bratislava Medical Journal | 🔗 DOI: 10.4149/BLL_2019_111

  • 📘 Gynaecological issues in women with bleeding disorders | 📅 2019 | 📰 The Journal of Haemophilia Practice | 🔗 DOI: 10.17225/jhp00142

  • 📘 Continuous infusion of coagulation factor concentrates during intensive treatment | 📅 2018 | 📰 Haemophilia | 🔗 DOI: 10.1111/hae.13331